Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
6.48
-0.01 (-0.15%)
May 2, 2025, 12:04 PM EDT - Market open
Kura Oncology Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Kura Oncology stock have an average target of 23.89, with a low estimate of 10 and a high estimate of 40. The average target predicts an increase of 268.67% from the current stock price of 6.48.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kura Oncology stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 10 | 10 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $32 → $11 | Buy | Maintains | $32 → $11 | +69.75% | May 2, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $28 | Buy | Reiterates | $28 | +332.10% | Apr 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +517.28% | Apr 28, 2025 |
| UBS | UBS | Strong Buy Maintains $27 → $14 | Strong Buy | Maintains | $27 → $14 | +116.05% | Mar 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +517.28% | Feb 27, 2025 |
Financial Forecast
Revenue This Year
77.77M
from 53.88M
Increased by 44.32%
Revenue Next Year
212.87M
from 77.77M
Increased by 173.73%
EPS This Year
-2.22
from -2.02
EPS Next Year
-2.03
from -2.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 200.5M | 473.8M | 507.2M | ||
| Avg | 77.8M | 212.9M | 206.4M | ||
| Low | n/a | 31.1M | 55.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 272.2% | 509.2% | 138.2% | ||
| Avg | 44.3% | 173.7% | -3.0% | ||
| Low | - | -60.1% | -74.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.00 | -0.48 | -0.21 | ||
| Avg | -2.22 | -2.03 | -2.18 | ||
| Low | -3.23 | -4.69 | -4.00 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.